1-(3-溴丙基)吡咯烷 | 113385-33-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-(3-溴丙基)吡咯烷
• 英文名称: 1-(3-bromopropyl)pyrrolidine
• 英文别名: 1-(3-Bromo-propyl)-pyrrolidine
• CAS: 113385-33-4
• 化学式: C₇H₁₄BrN
• 分子量: 192.099
• InChiKey: KLJFMOLCQITNEG-UHFFFAOYSA-N

物化性质

• 沸点：
  210.5±23.0 °C(Predicted)
• 密度：
  1.306±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-(3-溴丙基)吡咯烷 、 椭圆玫瑰树碱 在 potassium tert-butylate 作用下， 以 叔丁醇 为溶剂， 生成 GSA1137
  参考文献：
  名称：

  The Consequences of Overlapping G-Quadruplexes and i-Motifs in the Platelet-Derived Growth Factor Receptor β Core Promoter Nuclease Hypersensitive Element Can Explain the Unexpected Effects of Mutations and Provide Opportunities for Selective Targeting of Both Structures by Small Molecules To Downregulate Gene Expression

  摘要：

  The platelet-derived growth factor receptor beta (PDGFR-beta) signaling pathway is a validated and important target, for the treatment of certain malignant and nonmalignant pathologies. We previously identified a G-quadmplex-forming nuclease hypersensitive element (NHE) in the human PDGFR-beta promoter that putatively forms four overlapping G-quadruplexes. Therefore, we further investigated the structures and biological roles of the G-quadruplexes and i-motifs in the PDGFR-beta NHE with the ultimate goal of demonstrating an alternate and effective strategy for molecularly targeting the PDGFR-beta pathway. Significantly, we show that the primary G-quadruplex receptor for repression of PDGFR-beta is the 3'-end G-quadruplex, which has a GGA sequence at the 3'-end. Mutation studies using luciferase reporter plasmids highlight a novel set of G-quadruplex point mutations, some of which seem to provide conflicting results on effects on gene expression, prompting further investigation into the effect of these mutations on the i-motif-forming strand. Herein we characterize the formation of an equilibrium between at least two different i-motifs from the cytosine-rich (C-rich) sequence of the PDGFR-beta NHE. The apparently conflicting mutation results can be rationalized if we take into account the single base point mutation made in a critical cytosine run in the PDGFR-beta NHE that dramatically affects the equilibrium of i-motifs formed from this sequence. We identified a group of ellipticines: that targets the G-quadruplexes in the PDGFR-beta promoter, and from this series of compounds, we selected the ellipticine analog GSA1129, which selectively targets the 3'-end G-quadruplex, to shift the dynamic equilibrium in the full-length sequence to favor this structure. We also identified a benzothiophene-2-carboxamide (NSC309874) as a PDGFR-beta i-motif-interactive compound. In vitro, GSA1129 and NSC309874 downregulate PDGFR-beta promoter activity and transcript in the neuroblastoma cell line SK-N-SH at subcytotoxic cell concentrations. GSA1129 also inhibits PDGFR-beta-driven cell proliferation and migration. With an established preclinical murine model of acute lung injury, we demonstrate that GSA1129 attenuates endotoxin-mediated acute lung inflammation. Our studies underscore the importance of considering the effects of point mutations on structure formation from the G- and C-rich sequences and provide further evidence for the involvement of both strands and associated structures in the control of gene expression.

  DOI：

  10.1021/jacs.6b10028
• 作为产物：
  描述：

  1-allyl-pyrrolidine 在 2-甲基-2-丁烯 、 三甲基溴硅烷 、 氧气 、 copper(I) bromide 作用下， 以 二氯甲烷 、 水 为溶剂， 以52%的产率得到1-(3-溴丙基)吡咯烷
  参考文献：
  名称：

  铁（II）和铜（I）控制烯烃氢溴化反应的总区域选择性

  摘要：

  描述了一种可以完全控制烯烃氢溴化反应的区域选择性的新方法。在此，我们报告了一种使用 TMSBr 和氧作为常用试剂的自由基过程，其中在存在百万分之几的 Cu(I) 物种的情况下，反马尔可夫尼科夫产物的形成发生，而马尔可夫尼科夫产物的形成发生在存在 30 mol% 的溴化铁 (II)。密度泛函理论计算结合福井的激进磁化率支持获得的结果。

  DOI：

  10.1021/acs.orglett.1c02186

文献信息

• [EN] PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] ANTAGONISTES DE RECEPTEUR DE LA PROSTAGLANDINE D2 POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：MILLENNIUM PHARM INC

  公开号：WO2005100321A1

  公开（公告）日：2005-10-27

  Disclosed herein are compounds represented by Structural Formula: (I) and (I-A). Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply 'CRTH2' for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

  本文披露了由结构式(I)和(I-A)表示的化合物。还披露了利用这些化合物抑制称为趋化剂受体同源分子表达在Th2上的G蛋白偶联受体，简称为'CRTH2'，用于治疗炎症性疾病。结构式(I)和(I-A)中的变量在此处被定义。
• [EN] 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS DE 1,2,4-OXADIAZOLE EN TANT QU'AGONISTES DU RÉCEPTEUR X DU FOIE
  申请人：NOVARTIS AG

  公开号：WO2021105857A1

  公开（公告）日：2021-06-03

  Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I'), or pharmaceutical composition described herein.

  本文提供了用于治疗睑腺功能障碍（MGD）的化合物和药物组合物，包括向需要的受试者施用公式（I）的化合物或公式（I'）的化合物的治疗有效量，或本文所描述的药物组合物。
• [EN] NEW TETRACYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS TÉTRACYCLIQUES
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2009055828A1

  公开（公告）日：2009-04-30

  This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3- b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  这项披露涉及可能用于调节个体组织胺受体的新四环化合物。在一个实施例中，这些化合物是四环[4,3- b]吲哚类化合物。此外还提供了包含这些化合物的药物组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• PGD2 receptor antagonists for the treatment of inflammatory diseases
  申请人：Ghosh Shomir

  公开号：US20050256158A1

  公开（公告）日：2005-11-17

  Disclosed herein are compounds represented by Structural Formula (I) and (I-A): Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply “CRTH2” for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

  本文揭示了由结构式（I）和（I-A）表示的化合物：还披露了利用这些化合物抑制称为Th2表达的G蛋白偶联受体的化学引诱受体同源分子，简称“CRTH2”，用于治疗炎症性疾病。结构式（I）和（I-A）中的变量在此处被定义。
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2010007374A1

  公开（公告）日：2010-01-21

  The invention provides kinase inhibitor compounds of the formula (1): or salts, solvates, tautomers or N-oxides thereof; wherein X is O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRC or NRcSO2; m is 0-2; n is 0-1; q is 0-2; A is C1-6 alkylene optionally interrupted by O; R1 is halogen, cyano, nitro, an optionally substituted acyclic C1-6 hydrocarbon group, optionally substituted C3-7 cycloalkyl, optionally substituted phenyl, optionally substituted five membered heteroaryl, NR2R3, Ra-Rb, O-Rb or C(O)NR2R8; R4 is fluorine, chlorine, methyl or cyano; R2 is hydrogen or optionally substituted C1-4 alkyl; R3 is Ra-Rb; or NR2R3 forms a 4 to 7 membered non-aromatic heterocyclic ring; Ra is a bond, C(X2), C(X2)X1, SO, SO2 or SO2NRc; Rb is hydrogen or an optionally substituted 3 to 7- membered carbocyclic or heterocyclic ring or an optionally substituted C1-12 acyclic hydrocarbon group; Rc is hydrogen or a C1-4 hydrocarbon group; Rd is O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRC, SO2NRc or NRcSO2; X1 is O, S or NRc; X2 is =0, =S or =NRc; but excluding the compound wherein m, n and q are all O, A is CH2 and NR2R3 is a 2-phenylmorpholin-4-yl group.

  这项发明提供了化合物的激酶抑制剂的结构式（1）或其盐、溶剂合物、互变异构体或N-氧化物；其中X为O、CO、X1C（X2）、C（X2）X1、X1C（X2）X1、S、SO、SO2、NRc、SO2NRC或NRcSO2；m为0-2；n为0-1；q为0-2；A为C1-6烷基，可选地由O中断；R1为卤素、氰基、硝基、可选地取代的非环状C1-6烃基、可选地取代的C3-7环烷基、可选地取代的苯基、可选地取代的五元杂环烃基、NR2R3、Ra-Rb、O-Rb或C（O）NR2R8；R4为氟、氯、甲基或氰基；R2为氢或可选地取代的C1-4烷基；R3为Ra-Rb；或NR2R3形成4至7成员非芳杂环烃环；Ra为键、C（X2）、C（X2）X1、SO、SO2或SO2NRc；Rb为氢或可选地取代的3至7成员的碳环或杂环环或可选地取代的C1-12非环烃基；Rc为氢或C1-4烃基；Rd为O、CO、X1C（X2）、C（X2）X1、X1C（X2）X1、S、SO、SO2、NRC、SO2NRc或NRcSO2；X1为O、S或NRc；X2为=0、=S或=NRc；但不包括当m、n和q都为O，A为CH2，NR2R3为2-苯基吗啡啉-4-基团的化合物。